| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 103,764 | 121,551 | ||
| License agreement receivable | 17,500 | - | ||
| Prepaid expenses and other current assets | 2,825 | 2,165 | ||
| Total current assets | 124,089 | 123,716 | ||
| Restricted cash | 1,801 | 1,794 | ||
| Property and equipment | 12,139 | - | ||
| Less accumulated depreciation | 8,460 | - | ||
| Property and equipment, net | 3,679 | 4,018 | ||
| Operating lease right-of-use asset | 4,125 | 4,285 | ||
| Total assets | 133,694 | 133,813 | ||
| Accounts payable | 2,300 | 4,097 | ||
| Accrued expenses | 8,952 | 5,621 | ||
| Deferred revenue, current portion | 43,846 | 42,278 | ||
| Operating lease liability, current portion | 1,303 | 1,264 | ||
| Total current liabilities | 56,401 | 53,260 | ||
| Deferred revenue, net of current portion | 25,498 | 28,632 | ||
| Operating lease liability, net of current portion | 5,960 | 6,302 | ||
| Common stock warrant liabilities | 53,930 | 38,550 | ||
| Total liabilities | 141,789 | 126,744 | ||
| Common stock, 0.0001 par value 600,000,000 shares authorized at september 30, 2025 and 200,000,000 shares authorized at december 31, 2024 51,829,013 shares issued and outstanding at september 30, 2025 45,756,773 shares issued and outstanding at december 31, 2024 | 5 | 5 | ||
| Additional paid-in capital | 421,049 | 419,926 | ||
| Accumulated deficit | -429,149 | -412,862 | ||
| Total stockholders' (deficit) equity | -8,095 | 7,069 | ||
| Total liabilities and stockholders' (deficit) equity | 133,694 | 133,813 | ||
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)